What is OBSOLETE: Subcutaneous myiasis?
Subcutaneous myiasis is a parasitic condition in which fly larvae (maggots) infest and develop within the subcutaneous tissue (the layer of tissue just beneath the skin). This is not a genetic disease but rather an infectious/parasitic condition caused by the larvae of certain fly species, most commonly Dermatobia hominis (human botfly) and Cordylobia anthropophaga (tumbu fly). The Orphanet entry for this condition is marked as OBSOLETE, indicating it has been retired or reclassified within the Orphanet rare disease nomenclature. The condition manifests as a painful, boil-like swelling or nodule in the skin, often with a central punctum (small opening) through which the larva breathes. Patients may experience itching, a sensation of movement beneath the skin, serous or serosanguinous discharge, and secondary bacterial infection. The lesions most commonly occur on exposed areas of the body. Subcutaneous myiasis is predominantly seen in tropical and subtropical regions and is associated with travel to endemic areas. Treatment typically involves removal of the larva, which can be accomplished through various techniques including occlusion of the breathing pore (using petroleum jelly, bacon strips, or similar materials to force the larva to the surface), manual extraction, or minor surgical excision. Antibiotics may be prescribed if secondary bacterial infection occurs. The prognosis is generally excellent once the larva is completely removed. Prevention strategies include use of insect repellent, protective clothing, and proper ironing of clothes dried outdoors in endemic regions to kill deposited eggs.
- Age of Onset
- Variable
- Can begin at different ages, from infancy through adulthood
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for OBSOLETE: Subcutaneous myiasis.
View clinical trials →Clinical Trials
View all trials with filters →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
No actively recruiting trials found for OBSOLETE: Subcutaneous myiasis at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for OBSOLETE: Subcutaneous myiasis.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to OBSOLETE: Subcutaneous myiasis.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Subcutaneous myiasis.
Start the conversation →Latest news about OBSOLETE: Subcutaneous myiasis
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for OBSOLETE: Subcutaneous myiasis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about OBSOLETE: Subcutaneous myiasis
What is OBSOLETE: Subcutaneous myiasis?
Subcutaneous myiasis is a parasitic condition in which fly larvae (maggots) infest and develop within the subcutaneous tissue (the layer of tissue just beneath the skin). This is not a genetic disease but rather an infectious/parasitic condition caused by the larvae of certain fly species, most commonly Dermatobia hominis (human botfly) and Cordylobia anthropophaga (tumbu fly). The Orphanet entry for this condition is marked as OBSOLETE, indicating it has been retired or reclassified within the Orphanet rare disease nomenclature. The condition manifests as a painful, boil-like swelling or nod
Frequently asked questions about OBSOLETE: Subcutaneous myiasis
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is OBSOLETE: Subcutaneous myiasis?
OBSOLETE: Subcutaneous myiasis is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:165961). Inheritance pattern depends on the specific subtype. Age of onset is generally variable. For verified primary sources, see the UniteRare OBSOLETE: Subcutaneous myiasis page.
Are there FDA-approved treatments for OBSOLETE: Subcutaneous myiasis?
Approved treatments for OBSOLETE: Subcutaneous myiasis are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials for OBSOLETE: Subcutaneous myiasis?
Active clinical trials for OBSOLETE: Subcutaneous myiasis are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.
How do I find a specialist for OBSOLETE: Subcutaneous myiasis?
Verified OBSOLETE: Subcutaneous myiasis specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full OBSOLETE: Subcutaneous myiasis page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.